A rapid and sensitive analytical method for udenafil in rat plasma was developed and validated using liquid chromatography-tandem mass spectrometry (LC-MS/MS). This chromatographic procedure was then applied to the in vivo pharmacokinetic studies in rats for determining the advantages of intranasal administration of the drug over oral administration. Using liquid-liquid extraction (LLE), udenafil and the internal standard (IS) sildenafil were extracted with dichloromethane from 100 m ml of plasma samples. Chromatographic separation was performed using Pursuit XRS C 18 column (50 mm؋2.1 mm, i.d., 3 m mm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min. Detection and quantification was performed by mass spectrometry using the multiple reaction-monitoring mode at m/z 517.4→283.1 for udenafil and m/z 475.3→100.0 for IS. Results showed that the developed method was sensitive and specific for udenafil. Linearity was obtained in the range of 0.5-1000 ng/ml. The coefficient of variation of both intra-and inter-day validation were below 11.6% and the intraand inter-day accuracy ranged from 91.5 to 109.9%. Udenafil concentration was successfully measured from plasma after intranasal as well as after intravenous or oral administration at clinical dose (1.67 mg/kg) in rats. Moreover, the T max values obtained from pharmacokinetic studies suggested that administration of udenafil intranasally could be more effective than by the oral route.
Udenafil, (5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulphonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one), is a potent and selective inhibitor of phosphodiesterase type V (PDE5) like sildenafil, which catabolizes cyclic guanosine monophosphate (cGMP) in the corpus cavernosum (Fig. 1) . 1, 2) cGMP level is important for the maintenance of erection because, together with nitric oxide (NO), it is involved in the relaxation of the smooth muscles of the corpus cavernosum. Udenafil (Zydena ® ), currently marketed in Korea, was developed by Dong-A Pharmaceutical Co. (Yongin, South Korea) for oral administration to male patients suffering from erectile dysfunction.
The absolute oral bioavailability of udenafil at a dose of 30 mg/kg is known to be 38.0% in rats, 3) but that in human has not been reported. The absorption of udenafil from rat intestinal tract is known to be complete (about 99% of oral dose of 30 mg/kg).
3) Thus, the relatively low reported bioavailability of 38% may be due to hepatic, gastric and intestinal first-pass effect.
3) T max in rats is reported to be 35.5Ϯ12.1 min at a dose of 30 mg/kg, 3) while that in human is 1.5 h (1-3 h) at 100 mg dose to healthy male. 4) However, this T max needs to be shortened in order to satisfy the patient's need in the erectogenic market as in the case of Avanafil, a short-acting drug which exerts its pharmacological effect within 30 min. 5) Studies showed that compared to oral administration, nasal delivery could enhance relative bioavailability while shortening the T max . An example is in the study of the nasal administration of sildenafil citrate microemulsions compared to the oral route. 6) It is therefore very likely that udenafil in nasal formulation could also achieve rapid onset time and improved bioavailability by avoiding the first-pass effects in the liver and intestine. 7) Prior to formulation studies, pre-clinical animal studies need to be conducted, which should be accompanied with a sensitive analysis system. HPLC with UV detector has been widely used for the quantitative analysis of udenafil. 8, 9) But low sensitivity and long retention times of these methods have not allowed application for clinical dose detection. Until recently, the pharmacokinetic studies in animal model therefore had to be conducted at high doses (30 mg/kg) because the lower limit of quantification (LLOQ) was about 5 ng/ml. 9) Moreover, the large plasma volume (1 ml), used in the reports of udenafil analysis in human plasma by HPLC-MS/MS and UPLC-MS/MS systems, is inadequate for animal studies. 4, 10, 11) Moreover, in vivo pharmacokinetic studies in animal models require a sensitive analytical system that can be performed with minimal plasma sample. Thus, for a more sensitive and rapid analysis of udenafil, an LC-MS/MS system could replace previous methods.
Herein, we report on the development and validation of a rapid and sensitive analytical method of udenafil in rat plasma (100 ml) by LC-MS/MS and its application to pharmacokinetic studies in rats. This method will be applied for the analysis of drug concentration in plasma after intravenous, intranasal and oral administrations in rats. The method developed will aim to be able to detect plasma concentration for the dose of 1.67 mg/kg based on the commercial 100 mg udenafil oral tablet for a 60 kg adult.
Rapid and Sensitive Determination of Udenafil in Plasma by LC-MS/MS for Intranasal Pharmacokinetic Study in Rats

Experimental
Chemicals Udenafil (DA-8159) and sildenafil citrate (internal standard) were gifts from Dong-A Pharmaceutical Co. (Yongin, Korea). HPLC-grade acetonitrile and methanol were purchased from Fisher Scientific (Fair Lawn, NJ, U.S.A.). Double distilled water was prepared by a Milli-Q water purification system (Millipore Corp., Bedford, MA, U.S.A.). All other reagents were analytical grade or better and obtained from Sigma-Aldrich (St. Louis, U.S.A.).
Liquid Chromatography Conditions The HPLC Agilent 1200 Series equipped with a binary pump, a degasser and high performance auto-sampler with a thermostatted column compartment were used. Chromatographic separations were performed using a mobile phase composed of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) with a flow rate of 0.2 ml/min. Pursuit XRS C 18 column (50 mmϫ2.1 mm, 3 mm, Varian Inc., CA, U.S.A.) was used and the column temperature was maintained at 35°C. The temperature of auto-sampler was conditioned at 10°C and the injection volume was 5 ml.
Mass Spectrometry Conditions API 3200 triple quadrupole mass spectrometer (Applied Biosystems MDS SCIEX, Toronto, Canada) was operated with an electrospray ionization (ESI) interface in positive ionization mode. The working parameters of the mass spectrometer were the following: 5500 V of ion spray voltage, 91 V of declustering potential for analyte and 76 V for IS, 550°C of source temperature, 8.5 V of entrance potential, 35 psi of ion source gas (gas 1) and 50 psi of ion source gas (gas 2). Quantification was performed in multiple-reaction monitoring (MRM) mode with specific ion transitions of protonated precursor ion to product ion at m/z 517.4→ 283.1 for analyte and at m/z 475.3→100.0 for internal standard, respectively. The optimized collision energy was 59 eV for udenafil and 43 eV for internal standard, respectively. Nitrogen was used as the desolvation and cone and argon gas was used as the collision gas. Dwell time of 150 ms per channel was used for acquiring MRM data.
Preparation of Calibration Standards and Quality Control Samples A primary stock solution of udenafil (100 mg/ml) was prepared with methanol and working standard solution was prepared by the dilution with methanol. A primary stock solution of internal standard (50 mg/ml) was prepared in a 50 : 50 volume ratio mixture of methanol and double distilled water (DDW). A working stock solution of internal standard (1 mg/ml) was prepared by diluting an aliquot of primary stock solution with methanol and DDW mixture (50 : 50, v/v). Calibration standards of udenafil (0.5, 1, 5, 10, 50, 100, 500, 1000 ng/ml) were prepared by spiking the working standard solutions into pooled drug-free rat plasma. All the stock solutions were stored at 4°C until analysis. Quality control (QC) samples were prepared by individual spiking in blank plasma at six different concentration levels [0.5 ng/ml (lower limit of quantitation, LLOQ), 2 and 10 ng/ml (QC low), 100 and 300 ng/ml (QC medium) and 800 ng/ml (QC high)] and stored at 4°C until analysis.
Sample Preparation Liquid-liquid extraction (LLE) method was used for extraction of udenafil from rat plasma. Briefly, 20 ml of internal standard solution (1 mg/ml) and 100 ml plasma were mixed. After the addition of 1 ml of dichloromethane, the mixture was vortexed for 10 min, followed by centrifugation at 16100 g for 10 min. The organic phase (0.9 ml) was transferred into another tube and evaporated at 50°C under a gentle stream of nitrogen. The residue was reconstituted in 100 ml of acetonitrile and DDW mixture (90 : 10, v/v) and centrifuged at 16100 g for 1 min. The supernatant was transferred into the vial and 5 ml was injected into the analytical column.
Method Validation The software used for quantification was Analyst 1.4.2 (Applied Biosystems, Foster City, CA, U.S.A.). To evaluate linearity, calibration curves were prepared and assayed on three different days. The linearity of the assay was determined by analysis of prepared calibration standard samples. The concentration of standard samples for plotting the calibration curve was 0.5, 1, 5, 10, 50, 100, 500 and 1000 ng/ml. The results were fitted to linear regression analysis using 1/x 2 as weighting factor. The calibration curve had a correlation coefficient of 0.995 or better. The lower limit of quantification (LLOQ) was determined for udenafil, based on two criteria: (a) the analyte response at LLOQ had to be at least ten times higher than that of baseline noise and (b) the analyte response at LLOQ could be determined with sufficient precision and accuracy, i.e., precision of 20% and accuracy of 80-120%. Calculations were based on five repeats of three blank plasma batches. The selectivity of the method was demonstrated by comparing chromatograms of blank plasma samples, plasma samples spiked with udenafil and internal standard, and plasma samples obtained from rats administrated with udenafil. Chromatographic peaks were distinguished by retention time and multiple reaction monitoring (MRM) response. Intraassay precision and accuracy were determined by analyzing five replicates of each spiked QC sample on a single assay. Inter-assay precision and accuracy were determined by analyzing one QC sample per day at each concentration for three different days. The acceptable intra-and inter-day precision is required to be less than 15% and the acceptable accuracy is required to be within Ϯ15% for all QC samples. Recovery was determined by comparing the peak area of QC samples in rat plasma with those of standards prepared in neat solution. To determine the matrix effect, udenafil was spiked at each concentration in processed blank plasma and the peak area of post-extraction spiked samples was compared with that of neat standard samples. Stability tests of the analyte in plasma samples were performed under various storage conditions. For short-term stability test, the QC samples at four concentrations (2, 30, 300, 800 ng/ml) were kept at room temperature
Application to Pharmacokinetic Study Male Sprague-Dawley (SD) rats (250-300 g of body weight) were obtained from Orient Bio Inc. (Korea) and used in all in vivo pharmacokinetic studies. Rats were maintained in a light-controlled room kept at a temperature of 22Ϯ2°C and a relative humidity of 55Ϯ5% (Animal Center for Pharmaceutical Research, College of Pharmacy, Seoul National University, Korea). The experimental protocols involving animal study were approved by the Animal Care and Use Committee of the College of Pharmacy, Seoul National University. The permission number of animal experiment is "SNU-200909-33." Femoral artery and vein were cannulated with a polyethylene tube (PE-50, Clay Adams, Parsippany, NJ, U.S.A.) under anesthesia and blood was collected from the artery cannula. Considering the clinical dose of udenafil in human (100 mg for 60 kg adult), 1.67 mg/kg was administrated in rats by intravenous, intranasal, and oral routes (nϭ3-4). For intravenous and oral administrations, 1.6 mg/ml udenafil in 0.05 M citric acid solution was used, while 40 mg/ml in dimethyl sulfoxide (DMSO) and DDW mixture (85 : 15, v/v) was used for nasal administration. Blood sample was collected at predetermined time intervals (1, 5, 15, 30, 60, 120, 180, 240, 360, 480 min) after intravenous and intranasal administrations, while at 5, 15, 30, 45, 60, 75, 90, 120, 180 and 240 min after oral administration. After each sampling, heparinized blood samples were centrifuged at 16100 g for 5 min. And then plasma samples were collected and stored at Ϫ70°C until analyzed. The pharmacokinetic parameters were calculated by the WinNonlin (version 2.1, Scientific Consulting, KY, U.S.A.) program. Statistical analysis was performed using analysis of variance (ANOVA). All the experiments were performed at least three times and the data were represented as meanϮstandard deviation (S.D.).
Results and Discussion LC-MS/MS Conditions
The chemical structures of udenafil and sildenafil are shown in Fig. 1 . The structural similarity between the two compounds was the reason why sildenafil was chosen as the internal standard (IS). The MS/MS parameters were optimized for both udenafil and IS and quantification was performed in the positive ion mode using MRM. The analytes showed a strong mass response at electrospray ionization (ESI) mode. As shown in Fig. 2 , the fullscan mass spectra displayed strong intensity at m/z 517.4→283.1 for udenafil and m/z 475.3→100.0 for IS. Retention times of udenafil and IS were about 1.9 and 0.9 min, respectively and the total run time was 2.5 min (Fig. 3) .
Sample Preparation Three different methods, i.e., protein precipitation, solid phase extraction (SPE) and LLE, were investigated during preliminary studies for sample preparation. Among those methods, LLE method which showed the highest sensitivity for both udenafil and IS was therefore selected as the final sample preparation method. The extraction solvent for the LLE method was then selected based on recovery rates which were 44.0, 78.8 and 61.0%, respectively for ether, dichloromethane and their mixture (ether : dichloromethaneϭ3 : 2) at 800 ng/ml of udenafil. Thus, dichloromethane was selected as the extraction solvent throughout the experiments. Method Validation The calibration curves (nϭ3) were linear over the range of 0.5-1000 ng/ml. A typical equation of the calibration curve was as follows: yϭ0.0408xϩ0.0001 (r 2 ϭ0.997), where y represents the peak area ratios of udenafil to IS and x represents the concentration of udenafil. The LLOQ was 0.5 ng/ml for udenafil with acceptable signal to noise (S/N) ratio (14.1) and its inter-day precision and accuracy were 1.4% and 101.7%, respectively ( Table 1 ). The representative chromatograms of blank plasma samples, plasma samples spiked with udenafil and IS, and plasma samples obtained from rats intranasally administered with udenafil are depicted in Fig. 3 . As shown in Fig. 3 , no significant interfer-ence from endogenous substance in the blank plasma was observed. Six concentration levels of QC samples were validated to estimate the precision and accuracy. The intra-day precision and accuracy were obtained by the analysis of five QC replicates. The accuracy was within the range of 95.2-109.9% with 1.4-11.6% of precision. On the other hand, the inter-day accuracy and precision were evaluated on three different days. The accuracy for udenafil was within the range of 91.5-101.7% with 0.5-7.4% of precision ( Table 1) . The mean values of absolute recovery for udenafil when extracted by LLE at 2, 30, 300 and 800 ng/ml were ranged from 63.0 to 81.6%, while that for the IS was 64.6% (nϭ3). The matrix effect was ranged from 100 to 127%. Stability test was performed in various storage conditions. As shown in Table 2 , udenafil was stable at the four QC concentration levels. Udenafil was stable in rat plasma after being placed at room temperature for 6 h and at Ϫ70°C for 30 d. Three freeze-thaw cycles had no effect on the stability of udenafil according to these results. Samples placed in the autosampler at 10°C for 18 h showed 93.0-107.8% accuracy and 3.9-11.2% precision. The analytical method that have been previously described of udenafil by HPLC with UV detection have several disadvantages: the requirement of time-consuming extraction process after sample alkalization, long chromatographic run times (ca. 20 min), and lower sensitivity and relatively large sample volume. 8, 9) The LC-MS/MS analysis was also reported but have not exhibited enough sensitivity (2 ng/ml of LLOQ) and is a method with relatively long run time (4.5 min). 10) Moreover, although ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) has been reported for the analysis of udenafil in human plasma, it required equipments causing additional cost with LLOQ (1 ng/ml) higher than what is required in this study. 11) Considering the sensitivity, cost, required plasma volume and run time, the established analytical procedure in this investigation seems to be the most appropriate method for the in vivo pharmacokinetic study of udenafil.
Application to Pharmacokinetic Studies in Rats HPLC-MS/MS assay developed in this study was successfully applied to the pharmacokinetic study of udenafil after intravenous, intranasal and oral administration to the rat. Mean concentrations in plasma-time profiles of udenafil are shown in Fig. 4 . The representative pharmacokinetic parameters are listed in Table 3 . T max values of udenafil after oral and intranasal administration were 26.3Ϯ7.5 min and 2.3Ϯ 2.3 min, respectively. This implies that more rapid onset of action could be attained with intranasal administration compared to oral administration (pϽ0.01). C max and AUC 0-inf values obtained from intranasal administration were higher than those of oral administration (pϽ0.01). Absolute bioavailability after intranasal administration of udenafil (22.2%) was higher than that of oral administration (6.03%). In a previous study, it was suggested that the absolute oral bioavailability (F) of udenafil might be influenced by the sat- uration of intestinal first-pass effect.
3) The reported F values of udenafil at dose of 30, 50 and 100 mg/kg in rats after oral administration were 38.0, 55.6 and 104%, respectively. At clinical dose (1.67 mg/kg) in this investigation, low oral bioavailability (6.03%) seemed to be related with intestinal first-pass effect. Moreover, it was also reported that udenafil could be a substrate of the P-glycoprotein (P-gp) efflux transporter in Caco-2 cell monolayer study. 12) Since intranasal route can bypass the first-pass effect in the intestine, 13) it could result in higher nasal bioavailability than oral administration. Low aqueous solubility of udenafil indicates that nasal bioavailability and absorption rate could be further improved by optimizing formulations, including permeation enhancers and solubilizers. Additionally, results of in vivo pharmacokinetic study suggest that nasal delivery could reduce the clinical dose as well as significantly shorten the waiting time (1.5-2 h) after taking the drug, which is one of the major patient incompliance of Zydena ® oral tablets. The sensitive analysis method developed in this study could further be useful for the development and in vivo evaluation of an intranasal delivery system of udenafil.
Conclusion
A rapid, sensitive and selective LC-MS/MS method was developed and validated for the determination of udenafil in rat plasma. The low LLOQ value (0.5 ng/ml), low plasma volume (0.1 ml) and relatively short running time (2.5 min) obtained are useful parameters for quantitating udenafil at clinical dose. Results of the developed method were reproducible and no degradation of drug was observed during the whole analytical process. Pharmacokinetic studies in rats at a clinical dose showed higher bioavailability and faster onset of action after intranasal administration compared to those of oral administration, which could guarantee improved patient compliance and suggest the feasibility of further developing nasal delivery systems of udenafil. 
